Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-04-04 Director's Dealing
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders and Others' (최대주주등소유주식변동신고서) filed with the Korean regulatory authority (DART). It details specific share transactions (purchases) made by company executives (directors/officers) and the resulting changes in their ownership stakes. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2024-04-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by the National Pension Service regarding their holdings in HanAll Biopharma. This is a standard regulatory filing in South Korea (DART system) used to disclose changes in major shareholdings. Since it specifically details the change in ownership levels by a major shareholder, it falls under the 'Major Shareholding Notification' category.
2024-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed, including financial statement reporting, director appointments, and audit committee member appointments. This document is the official record of the voting results from the Annual General Meeting, which falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-03-28 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of an outside director (Jung Heon) at HanAll Biopharma. This falls under the category of Board/Management Information, as it specifically concerns changes to the board composition.
2024-03-28 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for HanAll Biopharma Co., Ltd. for the fiscal year 2023. It includes the independent auditor's report from Samjong KPMG, the audited financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and the accompanying notes. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) or business overview typically found in a full annual report, and it is not an announcement of a report (RPA) because it contains the full financial data and audit opinion. FY 2023
2024-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is a mandatory disclosure for insiders (directors/executives) reporting their personal share transactions, which corresponds to the 'Director's Dealing' category.
2024-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.